drugset
drugset / Trial / NCT02042950

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

NCT02042950 ↗

Phase 2 Terminated 6 enrolled M.D. Anderson Cancer Center Onyx Therapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if carfilzomib can help control relapsed or refractory MCL. The safety of this drug will also be studied.

Timeline

Start
2014-07-14
Primary completion
2017-12-20
Completion
2017-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 56 mg/m2 Intravenous

Indications

lymphoma